Clinical Chemistry and Laboratory Medicine (CCLM) · 2022 · 26 citations · 14 references
MedicineNeurologyNeuroscienceDementiaEarly DetectionNeurodegenerationAlzheimer DiseaseBiomarkers Of NeurodegenerationCerebrospinal Fluid BiomarkersCognitive ImpairmentDementia BiomarkersDementia DiagnosisAlzheimer's Disease DiagnosisAnalytical Methods DevelopmentCerebrospinal Fluid Neurodegeneration MarkersCognitive BiomarkersEarly Detection Of DementiaImmunoassaysLot-to-lot VariabilityMild Cognitive Impairment Diagnosis
OBJECTIVES: CSF immunoassays (Roche Diagnostics International Ltd), and adjusted existing cut-offs, to evaluate their potential utility in clinical routine. METHODS: Analytical performance was assessed using CSF samples measured with Elecsys CSF Gen II immunoassays on cobas e analyzers. Aβ42 Gen I/Gen II immunoassay method comparisons were performed (Passing-Bablok regression). Cut-off values were adjusted using estimated bias in biomarker levels between BioFINDER protocol aliquots/Gen I immunoassays and Gen II protocol aliquots/immunoassays. Distribution of Gen II immunoassay values was evaluated in AD, mild cognitive impairment (MCI), and cognitively normal cohorts; percentage observations outside the measuring range were derived. RESULTS: The Gen II immunoassays demonstrated good analytical performance, including repeatability, intermediate precision, lot-to-lot agreement (Pearson's r: ≥0.999), and platform agreement (Pearson's r: ≥0.995). Aβ42 Gen I/Gen II immunoassay measurements were strongly correlated (Pearson's r: 0.985-0.999). Aβ42 Gen II immunoassay cut-offs were adjusted to 1,030 and 800 ng/L, and pTau181/Aβ42 ratio cut-offs to 0.023 and 0.029, for Gen II and I protocols, respectively. No observations were below the lower limit of the measuring range; above the upper limit, there were none from the AD cohort, and 2.6 and 6.8% from the MCI and cognitively normal cohorts, respectively. CONCLUSIONS: Our findings suggest that the Gen II immunoassays have potential utility in clinical routine to aid diagnosis of AD.
14
The Lancet · 2021 · 4.9K citations · Full text
Life Sciences, Genetics, Neurology +17
Oskar Hansson, John Seibyl, Erik Stomrud et al. · Alzheimer s & Dementia · 2018 · 829 citations · Full text
Medicine, Neurology, Neuroscience +17
Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging
Suzanne E. Schindler, Julia Gray, Brian A. Gordon et al. · Alzheimer s & Dementia · 2018 · 302 citations · Full text
Medicine, Neurology, Neuroscience +16